Armata Pharmaceuticals ARMP
NYSE ARMP
$3.83 +0.08 (+2.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Armata Pharmaceuticals (ARMP) Gains from Sales and Divestitures (2012)

Updated

Armata Pharmaceuticals (ARMP) posted Gains from Sales and Divestitures of -$81,000 for FY2023.

Analysis

Armata Pharmaceuticals (ARMP) Gains from Sales and Divestitures (2012) Analysis & Trends

  • The FY2023 figure stands as the lowest annual Gains from Sales and Divestitures since FY2019.
  • Business Quant data shows ARMP's Gains from Sales and Divestitures at -$700,000 in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Armata Pharmaceuticals 137.07 Mn 84.78 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 -28,000.00
API Access

Armata Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ARMP&period=max&api_key=YOUR_API_KEY